Saltar al contenido
MilliporeSigma

C-093

Supelco

Cyclosporin A solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C62H111N11O12
Número de CAS:
Peso molecular:
1202.61
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−70°C

SMILES string

O=C(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@H](C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N([C@H](C(C)C)C(N(C)[C@@H]([C@@H]([C@H](C)C/C=C/C)O)C1=O)=O)C)=O)=O)=O)=O)=O)CC(C)C)=O)=O)CN(C)C([C@@H](N1)CC)=O

InChI

1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50?,51+,52-/m1/s1

InChI key

PMATZTZNYRCHOR-VPYFBNRVSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

A Certified Spiking Solution® of an immunosuppressant and narrow therapeutic index drug used to prevent rejection in organ transplantation. This certified calibration material is suitable for critical quantitative applications in clinical and diagnostic testing such as therapeutic drug monitoring assays to ensure patients remain within the drug′s narrow therapeutic range.  The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as cyclosporin A, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Application


  • Novel IgE crosslinking-induced luciferase expression method using human-rat chimeric IgE receptor-carrying mast cells: This study leverages Cyclosporin A′s immunosuppressive properties to explore new methodologies for investigating allergic responses. By utilizing Cyclosporin A to modulate immune cell activity, researchers have developed an innovative in vitro assay that significantly enhances our understanding of immune mechanisms, demonstrating Cyclosporin A′s pivotal role in immunological research and its application in developing more effective allergy treatments (Akiyama H et al., 2024).

  • Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics: This review discusses the critical role of Cyclosporin A in the development of nanocarrier systems for targeted drug delivery, particularly for ocular applications. Cyclosporin A′s effectiveness in preventing transplant rejection and its properties as a calcineurin inhibitor make it an excellent candidate for incorporation into advanced drug delivery systems, enhancing therapeutic efficacy and reducing systemic side effects (Datta D et al., 2024).

  • A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: Demonstrating Cyclosporin A′s utility in enhancing the efficacy of controlled-release drug systems, this study details the use of Cyclosporin A with a novel xanthan gum-based platform. This research emphasizes Cyclosporin A′s role in the pharmaceutical industry, particularly in improving drug delivery mechanisms that can be crucial for treating chronic conditions (Signorini S et al., 2024).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Related product

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk_germany

WGK 3

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jane Rasaiyaah et al.
Nature, 503(7476), 402-405 (2013-11-08)
Human immunodeficiency virus (HIV)-1 is able to replicate in primary human macrophages without stimulating innate immunity despite reverse transcription of genomic RNA into double-stranded DNA, an activity that might be expected to trigger innate pattern recognition receptors. We reasoned that
Tip W Loo et al.
Biochemistry, 52(41), 7167-7169 (2013-10-03)
There is no high-resolution crystal structure of the human P-glycoprotein (P-gp) drug pump. Homology models of human P-gp based on the crystal structures of mouse or Caenorhabditis elegans P-gps show large differences in the orientation of transmembrane segment 5 (TM5).
Maaike Kockx et al.
Pharmacology & therapeutics, 128(1), 106-118 (2010-07-06)
Cyclosporin A (CsA) is an immunosuppressant drug widely used in organ transplant recipients and people with autoimmune disorders. Long term treatment with CsA is associated with many side effects including hyperlipidemia and an increased risk of atherosclerosis. While its immunosuppressive
C E M Griffiths et al.
The British journal of dermatology, 155 Suppl 2, 1-16 (2006-06-16)
Immune-mediated dermatoses, such as psoriasis and atopic dermatitis, affect a significant proportion of the population. Although most cases are not life threatening, these diseases can have a profound effect on the sufferer's quality of life and that of their family.
Angela C Webster et al.
BMJ (Clinical research ed.), 331(7520), 810-810 (2005-09-15)
To compare the positive and negative effects of tacrolimus and ciclosporin as initial treatment for renal transplant recipients. Systematic review. Reports of comparative randomised trials of tacrolimus and ciclosporin identified by searches of Medline, Embase, the Cochrane Register of Controlled

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico